Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Research Progress of EGFR-TKIs Resistance and PD-L1 Expression in EGFR-Mutant Non-Small Cell Lung Cancer

Published:2024 Issue:01 Volume:14 Page:183-189
ISSN:2161-8712
Container-title:Advances in Clinical Medicine
language:
Short-container-title:ACM

Author:

温雅婷

Publisher

Hans Publishers

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

3. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

4. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

5. 刘丽萍, 刘苓霜. 程序性死亡蛋白1/程序性死亡蛋白配体1抑制剂在表皮生长因子受体突变晚期肺癌中的应用进展[J]. 中华肿瘤防治杂志, 2023, 30(1): 54-60.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP